Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

S. Stacchiotti, Maurizio Saponara, R. Frapolli, M. Tortoreto, D. Cominetti, S. Provenzano, T. Negri, G. P. Dagrada, A. Gronchi, C. Colombo, Brenda Vincenzi, G. Badalamenti, V. Zuco, S. L. Renne, P. Collini, C. Morosi, A. P. Dei Tos, E. Bello, S. Pilotti, P. G. CasaliM. D'Incalci, N. Zaffaroni

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel compounds to be tested in the clinic. This study was aimed at developing two preclinical models of SFT, assessing their predictive value in the clinic and selecting potential novel effective treatments. MATERIAL AND METHODS: Two dedifferentiated-SFT (D-SFT) models obtained from patients' biopsies were grown in immunodeficient mice. The antitumour activity on these models of doxorubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and eribulin was tested. Twelve SFT patients were treated with doxorubicin and DTIC. Response by RECIST, progression-free survival and overall survival were retrospectively evaluated, distinguishing malignant-SFT (M-SFT) and
Original languageUndefined/Unknown
Pages (from-to)84-92
Number of pages9
JournalEuropean Journal of Cancer
Publication statusPublished - Mar 1 2017


  • Anthracycline, Chemotherapy, Dacarbazine, Doxorubicin, Eribulin, Ifosfamide, Metastasis, Mice model, Sarcoma, Solitary fibrous tumour, Trabectedin, Treatment, Xenograft

Cite this